(A) Market preparation: Cetafen® tablet claimed to contain 325 mg PAR and 200 mg IBU | |||||||||
---|---|---|---|---|---|---|---|---|---|
Proposed method recovery %a | Standard addition technique | ||||||||
Ratio difference | |||||||||
Ratio difference | Mean centering | Constant center | Taken (μg/mL) | Recovery %a | |||||
PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU |
100.12 ± 0.62 | 101.34 ± 1.51 | 99.58 ± 0.53 | 100.52 ± 1.26 | 99.68 ± 0.95 | 100.44 ± 1.17 | 3.0 | 20.0 | 100.76 | 99.16 |
3.0 | 20.0 | 101.53 | 100.34 | ||||||
3.0 | 20.0 | 100.42 | 101.95 |
Standard addition technique | |||||||
---|---|---|---|---|---|---|---|
Mean centering | Constant center | ||||||
Taken (μg/mL) | Recovery %a | Taken (μg/mL) | Recovery %a | ||||
PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU |
3.0 | 20.0 | 98.14 | 100.96 | 3.0 | 20.0 | 100.37 | 99.02 |
3.0 | 20.0 | 100.33 | 100.55 | 3.0 | 20.0 | 98.43 | 100.55 |
3.0 | 20.0 | 101.08 | 101.13 | 3.0 | 20.0 | 100.85 | 99.89 |
(B) Market preparation: Parofen® tablet claimed to contain 500 mg PAR and 400 mg IBU | |||||||||
---|---|---|---|---|---|---|---|---|---|
Proposed method recovery %a | Standard addition technique | ||||||||
Ratio difference | |||||||||
Ratio difference | Mean centering | Constant center | Taken (μg/mL) | Recovery %a | |||||
PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU |
98.72 ± 0.89 | 100.74 ± 0.56 | 100.58 ± 0.93 | 101.22 ± 1.18 | 9936 ± 0.52 | 100.36 ± 1.03 | 3.0 | 20.0 | 100.54 | 99.96 |
3.0 | 20.0 | 101.24 | 101.31 | ||||||
3.0 | 20.0 | 101.43 | 100.63 |
Standard addition technique | |||||||
---|---|---|---|---|---|---|---|
Mean centering | Constant center | ||||||
Taken (μg/mL) | Recovery %a | Taken (μg/mL) | Recovery %a | ||||
PAR | IBU | PAR | IBU | PAR | IBU | PAR | IBU |
3.0 | 20.0 | 100.73 | 100.13 | 3.0 | 20.0 | 101.33 | 99.45 |
3.0 | 20.0 | 101.12 | 99.58 | 3.0 | 20.0 | 100.95 | 99.82 |
3.0 | 20.0 | 100.37 | 100.22 | 3.0 | 20.0 | 100.04 | 98.73 |